Nous Vita

Methodology

Last updated: July 2026

This page describes how Nous Vita evaluates supplements, compounds and protocols, checks them against your medicines and conditions, and grades the evidence behind every answer. We publish it so that users, clinicians and researchers can assess our work critically. Transparency is the foundation of trust, and trust is all we have.

Data Sources

Every claim in Nous Vita points at a document. The library behind it is 382 documents from 126 distinct publishers, and the tables on this page are generated from that library each time the site is built rather than written by hand, so they cannot quietly fall out of date. We do not use marketing materials, manufacturer claims, or affiliate content as evidence.

The library, as it stands today

Generated from the source library when this page was built. Nobody types these numbers in.

Who published it

  • Peer reviewed journals152
  • Government health agencies136
  • Summaries of other people's research45
  • Drug regulators and legislators31
  • Professional and clinical societies12
  • Clinical reference works6

What kind of document it is

  • Liver injury database entries124
  • Observational studies56
  • Randomised controlled trials36
  • Expert reviews35
  • Meta analyses35
  • Approved product labels26
  • Systematic reviews19
  • Clinical practice guidelines17
  • Mechanism studies13
  • Case reports10
  • Regulatory communications9
  • Trials that found no effect2

The institutions behind this work

Named organisations that stand behind a finding, largest first. Individual journals are not listed here — there are more than a hundred of them, and they are named on the findings themselves.

  • NIH National Institute of Diabetes and Digestive and Kidney Diseases 125
  • U.S. Food and Drug Administration 29
  • World Health Organization Collaborating Centre for Drug Statistics Methodology 6
  • American Diabetes Association 4
  • NIH Office of Dietary Supplements 3
  • Kidney Disease: Improving Global Outcomes (KDIGO) 2
  • National Kidney Foundation 2
  • American College of Cardiology/American Heart Association 1

Government health agencies

The largest single body of evidence we hold. It includes LiverTox, the clinical database of drug induced liver injury maintained by the NIH National Institute of Diabetes and Digestive and Kidney Diseases, which covers over 1,000 prescription and nonprescription medicines, herbal products and dietary supplements, each with a rated likelihood of liver injury. Alongside it sit the NIH Office of Dietary Supplements fact sheets, the National Institute on Alcohol Abuse and Alcoholism, and the World Health Organization's drug classification system. LiverTox is in the public domain; use of its data is acknowledged per NIDDK attribution guidelines.

Drug regulators and approved labelling

Prescribing information and safety communications from the U.S. Food and Drug Administration, New Zealand's Medsafe, and European Union medicines legislation. An approved label is the manufacturer's own account of what it is legally obliged to disclose, which makes it authoritative about the medicine and largely silent about the supplement. We use it for the first and never for the second.

The peer reviewed literature

Randomised controlled trials, meta analyses, systematic reviews, human pharmacokinetic studies, observational studies and case reports, cited one document at a time. We prioritise human data over test tube and animal work. We also deliberately keep trials that found nothing: a study showing that a suspected interaction does not actually occur is evidence, and discarding it would leave the library tilted towards alarm.

Clinical practice guidelines

Standards of care from professional bodies, among them the American Diabetes Association, Kidney Disease: Improving Global Outcomes, the National Kidney Foundation, the American Geriatrics Society and the American College of Cardiology. Guidelines rarely establish that an interaction exists; they establish what a clinician is expected to do about it, which is what most of our timing and monitoring advice rests on.

Summaries, and the limit we place on them

We also hold 45 monographs from academic centres and clinical reference works that summarise other people's primary research rather than reporting their own. These are excellent for finding evidence and poor for standing behind it, so the engine refuses to let one carry a claim by itself: adding a new fact whose only support is a summary is a build error. 25 older facts still rest on one, and rather than hide them we keep them on a published list that is only allowed to shrink. We tell you this because a source library that conceals its weakest tier is advertising, not disclosure.

How this was built, in plain terms

Most interaction checkers are a list of pairs. Somebody wrote down that this drug and that supplement do not mix, and the tool looks the pair up. Such a tool can only ever know what someone remembered to write down, and it has nothing to say about the combination nobody thought to check. Nous Vita is built the other way round, in five layers.

  1. 1

    We work out what you actually took

    You type a brand name, a nickname, or a spelling nobody agrees on. We resolve it to a substance — the molecule or the plant extract — so that fish oil, omega 3 and EPA/DHA all land in the same place. The registry holds 357 of them. Anything we cannot resolve is simply not checked, which is why every clear result on this site tells you our lists are incomplete rather than telling you that you are fine.

  2. 2

    Every substance joins the families it belongs to

    A substance is never only its own name. Warfarin is a vitamin K antagonist, an anticoagulant, and a drug with a narrow margin between the dose that works and the dose that harms — all at once, and each of those memberships carries different consequences. We maintain 61 such families, and every substance declares which ones it belongs to. This is why the tool can react to a medicine nobody ever wrote a pairwise entry for: it does not need to recognise the product, only the family.

  3. 3

    We model the harm, not the pair

    The thing that hurts you is bleeding, or a potassium level that disturbs your heart rhythm, or liver injury. It is not an abstract 'interaction'. So the harm is the root of the model, and each harm records the separate routes that lead to it. A supplement can raise bleeding risk entirely on its own, or only alongside one particular kind of blood thinner, and those are different facts resting on different evidence. We show you which one applies to you instead of collapsing both into a single warning that fits neither.

  4. 4

    Every claim carries its document

    Each of the 75 curated relationships in the engine points at one or more documents in the library, and records the sentence in that document that supports it. The number of them resting on nothing at all is 0. That is not a promise, it is a measurement: an automated check recomputes it and refuses to pass if it is anything other than zero, and the same check runs over the 33 guidance rules and 61 families. A confident warning with nothing behind it is worse than no warning.

  5. 5

    All of it runs on your device

    The registry, the families, the rules and the evidence library are compiled into the page itself when the site is built. Your regimen is evaluated in your browser, by code that arrived with the page. Nothing you enter is transmitted anywhere, because there is nowhere for it to go.

Evidence Grading

Every supplement recommendation and safety claim carries an evidence grade. We use a three tier system adapted from standard evidence-based medicine frameworks.

High

Supported by multiple randomized controlled trials with consistent findings, or a systematic review/meta-analysis. The effect is well characterized, and the direction of evidence is clear.

Moderate

Supported by at least one randomized controlled trial or multiple well designed observational studies. The evidence is suggestive but not conclusive. Effect sizes may vary across studies.

Low

Supported by mechanistic plausibility, animal studies, or preliminary human data only. The claim is biologically plausible but has not been confirmed in rigorous human trials.

How the Safety Checker Works

When you enter supplements and medications into Nous Vita, the Safety Checker performs two types of analysis, both running entirely in your browser.

First, it looks at each substance on its own. Some supplements carry a documented risk with no second ingredient required: a known likelihood of liver injury, drawn from the NIH LiverTox database and reported with the category it assigns; or a harm such as bleeding that the literature attributes to the supplement by itself. A standalone risk is reported as a standalone risk, and is not disguised as an interaction.

Second, it checks each substance against every other thing you take and against the conditions in your profile. This does not work by looking your pair up in a table. Each substance belongs to families, and our rules are written about families, so a rule about vitamin K antagonists reaches every vitamin K antagonist we know of. An interaction is reported when published evidence documents a clinically meaningful effect: altered absorption, metabolism or clearance; additive or opposing effects on the body; or documented adverse events. The checker reports the mechanism, the direction of the effect, and who said so.

Nous Vita works like an application on your device. Once the site has loaded, you can disconnect from the internet and everything still works: the safety checker, the regimen builder, the tracking dashboard. The interaction database is part of the site itself, loaded once at build time, not fetched from a server while you use it. No internet connection needed. In the future, if we offer optional encrypted cloud backup, that is the only feature that would need a connection, and it would be opt-in only.

Research Pipeline

We maintain an adversarial research pipeline to keep the knowledge base current and honest. New evidence is evaluated by multiple independent reviewers who are incentivized to find weaknesses in the evidence, not just support for existing conclusions. We explicitly look for studies that contradict our current assessments. When the evidence shifts, we update our recommendations and publish the rationale for the change. The pipeline includes systematic monitoring of PubMed for new supplement drug interaction publications, regular review of NIH LiverTox updates, and periodic re evaluation of existing evidence grades.

Limitations

Nous Vita is an informational tool, not a substitute for clinical judgment. Our analysis has important limitations that users and clinicians should understand.

The interaction database covers published, documented interactions. It does not cover theoretical interactions that lack published evidence, interactions with rare or newly approved medications that have limited post marketing data, or individual patient factors such as genetics, liver function, age, or polypharmacy burden. A result of no known interactions does not guarantee safety. The absence of evidence is not evidence of absence.

Our evidence library reflects what has been published and indexed. Rare or novel reactions may not be documented anywhere yet, and no source we hold accounts for individual susceptibility. This is sharpest for liver injury: the NIH LiverTox database is authoritative about the substances it has assessed, and silent about the rest. An absent entry means not assessed, and nothing more than that.

Supplement quality and composition vary by manufacturer. Nous Vita evaluates the substance, not specific brands. A product may contain fillers, contaminants, or different doses than labeled.

Updates and Versioning

The interaction database and evidence grades are updated as new research is published. Major updates are versioned and changelogs are published. The NIH LiverTox data is refreshed when NIDDK releases updates. Users can verify the last update date on this page.